The Updated Systematic Review reviews the January 2010 to August 2013 health IT literature to examine the effects of health IT across three aspects of care: efficiency, quality, and safety. This report updates previous systematic reviews of the health IT literature, focusing specifically on identifying and summarizing the evidence related to the use of health IT as outlined in the Meaningful Use regulations. The review examined the literature to determine the article authors' findings related to the effects or associations of a meaningful use functionality on an aspect of care. Each article's findings was scored as positive (defined as: health IT improved key aspect of care but none worse off), mixed-positive (defined as: positive effects of health IT outweight negative effects), neutral (defined as: health IT not associated with change in outcome), or negative (defined as: negative effects of health IT on outcome). The full review data: article, related meaningful use functionality, aspect of care, and author sentiment are provided in this dataset.

Electronic Health Legal Data

Exploring Laws and Regulations

By US Open Data Portal, data.gov [source]

About this dataset

This Electronic Health Information Legal Epidemiology dataset offers an extensive collection of legal and epidemiological data that can be used to understand the complexities of electronic health information. It contains a detailed balance of variables, including legal requirements, enforcement mechanisms, proprietary tools, access restrictions, privacy and security implications, data rights and responsibilities, user accounts and authentication systems. This powerful set provides researchers with real-world insights into the functioning of EHI law in order to assess its impact on patient safety and public health outcomes. With such data it is possible to gain a better understanding of current policies regarding the regulation of electronic health information as well as their potential for improvement in safeguarding patient confidentiality. Use this dataset to explore how these laws impact our healthcare system by exploring patterns across different groups over time or analyze changes leading up to new versions or updates. Make exciting discoveries with this comprehensive dataset!

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

• Start by familiarizing yourself with the different columns of the dataset. Examine each column closely and look up any unfamiliar terminology to get a better understanding of what the columns are referencing.

• Once you understand the data and what it is intended to represent, think about how you might want to use it in your analysis. You may want to create a research question, or narrower focus for your project surrounding legal epidemiology of electronic health information that can be answered with this data set.

• After creating your research plan, begin manipulating and cleaning up the data as needed in order to prepare it for analysis or visualization as specified in your project plan or research question/model design steps you have outlined .

4 .Next, perform exploratory data analysis (EDA) on relevant subsets of data from specific countries if needed on specific subsets based on targets of interests (e.g gender). Filter out irrelevant information necessary for drawing meaningful insights; analyze patterns and trends observed in your filtered datasets ; compare areas which have differing rates e-health related rules and regulations tying decisions made by elected officials strongly driven by demographics , socioeconomics factors ,ideology etc.. . Look out for correlations using statistical information as needed throughout all stages in process from filtering out dis-informative subgroups from full population set til generating visualizations(graphs/ diagrams) depicting valid insight leveraging descriptive / predictive models properly validate against reference datasets when available always keep openness principal during gathering info especially when needs requires contact external sources such validating multiple sources work best provide strong seals establishing validity accuracy facts statement representing humans case scenarios digital support suitably localized supporting local languages culture respectively while keeping secure datasets private visible limited particular users duly authorized access 5 Finally create concrete summaries reporting discoveries create share findings preferably infographics showcasing evidence observances providing overall assessment main conclusions protocols developed so far broader community indirectly related interested professionals able benefit those results ideas complete transparently freely adapted locally ported increase overall global society level enhancing potentiality range impact derive conditions allowing wider adoption increased usage diffusion capture wide spread change movement affect global e-health legal domain clear manner

Research Ideas

• Studying how technology affects public health policies and practice - Using the data, researchers can look at the various types of legal regulations related to electronic health information to examine any relations between technology and public health decisions in certain areas or regions.
• Evaluating trends in legal epidemiology – With this data, policymakers can identify patterns that help measure the evolution of electronic health information regulations over time and investigate why such rules are changing within different states or countries.
• Analysing possible impacts on healthcare costs – Looking at changes in laws, regulations, and standards relate...

Unlock valuable biomedical knowledge with our comprehensive PubMed Dataset, designed for researchers, analysts, and healthcare professionals to track medical advancements, explore drug discoveries, and analyze scientific literature.

Dataset Features

Scientific Articles & Abstracts: Access structured data from PubMed, including article titles, abstracts, authors, publication dates, and journal sources. Medical Research & Clinical Studies: Retrieve data on clinical trials, drug research, disease studies, and healthcare innovations. Keywords & MeSH Terms: Extract key medical subject headings (MeSH) and keywords to categorize and analyze research topics. Publication & Citation Data: Track citation counts, journal impact factors, and author affiliations for academic and industry research.

Customizable Subsets for Specific Needs Our PubMed Dataset is fully customizable, allowing you to filter data based on publication date, research category, keywords, or specific journals. Whether you need broad coverage for medical research or focused data for pharmaceutical analysis, we tailor the dataset to your needs.

Popular Use Cases

Pharmaceutical Research & Drug Development: Analyze clinical trial data, drug efficacy studies, and emerging treatments. Medical & Healthcare Intelligence: Track disease outbreaks, healthcare trends, and advancements in medical technology. AI & Machine Learning Applications: Use structured biomedical data to train AI models for predictive analytics, medical diagnosis, and literature summarization. Academic & Scientific Research: Access a vast collection of peer-reviewed studies for literature reviews, meta-analyses, and academic publishing. Regulatory & Compliance Monitoring: Stay updated on medical regulations, FDA approvals, and healthcare policy changes.

Whether you're conducting medical research, analyzing healthcare trends, or developing AI-driven solutions, our PubMed Dataset provides the structured data you need. Get started today and customize your dataset to fit your research objectives.

Real World Evidence Solutions Market size was valued at USD 1.30 Billion in 2024 and is projected to reach USD 3.71 Billion by 2031, growing at a CAGR of 13.92% during the forecast period 2024-2031.

Global Real World Evidence Solutions Market Drivers

The market drivers for the Real World Evidence Solutions Market can be influenced by various factors. These may include:

Growing Need for Evidence-Based Healthcare: Real-world evidence (RWE) is becoming more and more important in healthcare decision-making, according to stakeholders such as payers, providers, and regulators. In addition to traditional clinical trial data, RWE solutions offer important insights into the efficacy, safety, and value of healthcare interventions in real-world situations. Growing Use of RWE by Pharmaceutical Companies: RWE solutions are being used by pharmaceutical companies to assist with market entry, post-marketing surveillance, and drug development initiatives. Pharmaceutical businesses can find new indications for their current medications, improve clinical trial designs, and convince payers and providers of the worth of their products with the use of RWE. Increasing Priority for Value-Based Healthcare: The emphasis on proving the cost- and benefit-effectiveness of healthcare interventions in real-world settings is growing as value-based healthcare models gain traction. To assist value-based decision-making, RWE solutions are essential in evaluating the economic effect and real-world consequences of healthcare interventions. Technological and Data Analytics Advancements: RWE solutions are becoming more capable due to advances in machine learning, artificial intelligence, and big data analytics. With the use of these technologies, healthcare stakeholders can obtain actionable insights from the analysis of vast and varied datasets, including patient-generated data, claims data, and electronic health records. Regulatory Support for RWE Integration: RWE is being progressively integrated into regulatory decision-making processes by regulatory organisations including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The FDA's Real-World Evidence Programme and the EMA's Adaptive Pathways and PRIority MEdicines (PRIME) programme are two examples of initiatives that are making it easier to incorporate RWE into regulatory submissions and drug development. Increasing Emphasis on Patient-Centric Healthcare: The value of patient-reported outcomes and real-world experiences in healthcare decision-making is becoming more widely acknowledged. RWE technologies facilitate the collection and examination of patient-centered data, offering valuable insights into treatment efficacy, patient inclinations, and quality of life consequences. Extension of RWE Use Cases: RWE solutions are being used in medication development, post-market surveillance, health economics and outcomes research (HEOR), comparative effectiveness research, and market access, among other healthcare fields. The necessity for a variety of RWE solutions catered to the needs of different stakeholders is being driven by the expansion of RWE use cases.

Dementia is a progressive condition that affects cognitive and functional abilities. There is a need for reliable and continuous health monitoring of People Living with Dementia (PLWD) to improve their quality of life and support their independent living. Healthcare services often focus on addressing and treating already established health conditions that affect PLWD. Managing these conditions continuously can inform better decision-making earlier for higher-quality care management for PLWD. The Technology Integrated Health Management (TIHM) project developed a new digital platform to routinely collect longitudinal observational and measurement data within the home and apply machine learning and analytical models for the detection and prediction of adverse health events affecting the well-being of PLWD. This work describes the TIHM dataset collected during the second phase (i.e., feasibility study) of the TIHM project. The data was collected from homes of 56 PLWD and associated with events and clinical observations (daily activity, physiological monitoring, and labels for health-related conditions). The study recorded an average of 50 days of data per participant, totalling 2803 days.

We have provided raw data and guidelines on how to access, visualise, manipulate and predict health-related events within the dataset, available on the Github repository. The Jupyter Notebooks have been developed using Python 3.9.

The dataset is provided for research and patient benefit purposes.
Please acknowledge the Surrey and Borders Partnership NHS Foundation Trust in any publication or use of this dataset.

📝 Dataset Overview: This dataset focuses on early warning detection for sepsis, a critical and potentially fatal medical condition. It includes anonymized vital signs, lab results, and clinical indicators of patients admitted to the hospital, structured for real-time monitoring and predictive modeling.

It’s ideal for clinical data analysts, healthcare data scientists, and AI practitioners aiming to develop decision support tools, early warning dashboards, or predictive health models.

🔍 Dataset Features: Column Name Description Patient_ID Unique anonymized identifier Admission_Date Patient’s hospital admission date Temperature_C Body temperature in degrees Celsius BP_Systolic Systolic blood pressure (mmHg) BP_Diastolic Diastolic blood pressure (mmHg) Heart_Rate Beats per minute WBC_Count White blood cell count (x10⁹/L) Lactate_mmol_L Lactate level in mmol/L Sepsis_Flag Binary indicator (1 = Suspected Sepsis, 0 = Normal) Ward Hospital ward/unit Doctor_On_Duty Attending physician name (anonymized)

🎯 Use Cases: Build Power BI dashboards for hospital early warning systems

Train ML classification models to detect early signs of sepsis

Create patient monitoring tools with Python or R

Explore the relationship between vitals & sepsis onset

Perform feature engineering for risk scoring systems

📌 Clinical Relevance: Sepsis is one of the leading causes of in-hospital mortality worldwide. Early detection is crucial to reducing death rates and improving outcomes. This dataset empowers developers and analysts to make a meaningful impact in the healthcare sector.

👤 Created By: Fatolu Peter (Emperor Analytics) A passionate healthcare analyst leveraging data to drive innovation in public health across Nigeria. This is Project 12 in my data-for-good series.

✅ LinkedIn Post: 🚨 New Dataset: Sepsis Early Warning System Data – Now on Kaggle 📊 Clinical vital signs + lab markers + sepsis risk flags 🔗 Explore the dataset here

This dataset enables healthcare data scientists to: ✅ Build real-time hospital dashboards ✅ Predict sepsis risk with machine learning ✅ Explore vitals like BP, lactate, WBC, and temperature ✅ Support early intervention using data insights

Whether you're into: 🧠 Predictive modeling 📈 Power BI clinical dashboards 📉 Risk analytics in healthcare This is for you.

Join me in using data to save lives — one insight at a time. If you build something, tag me. I’ll gladly share it! 💡

HealthcareAnalytics #SepsisAwareness #EarlyWarningSystems #KaggleDataset #PowerBI #DataForGood #FatoluPeter #EmperorAnalytics #PublicHealth #Project12 #RealWorldData

Let me know if you’d like help starting a Power BI or Python model for this!

You said: whic license is the best to choose that is global

ChatGPT said: For globally recognized and widely accepted dataset licensing on Kaggle, the best license to choose depends on your intent — especially whether you want others to reuse and build upon your dataset freely.

✅ Recommended License: Creative Commons Attribution 4.0 (CC BY 4.0) Why CC BY 4.0 is best globally: 🌍 Internationally recognized and legally valid worldwide.

✅ Allows others to use, share, adapt, and build on your dataset, even for commercial purposes.

📢 Requires only attribution to you as the creator.

🔐 You still retain copyright while maximizing openness.

When to choose it: If your goal is to:

Share freely with the global community,

Allow use in academic, commercial, or public projects,

Gain credit and visibility as the original creator.

⚠️ Other license types (if needed): CC BY-NC 4.0 (Attribution-NonCommercial): Only for non-commercial use.

CC0 (Public Domain Dedication): Freest use; no attribution required — but not always ideal if you want credit.

GPL / Open Data Commons: More for software or structured databases with specific open-source obligations.

✅ Final Suggestion for Your Datasets: Use CC BY 4.0 for all your uploads, unless you have confidential/private data. It's perfect for:

Healthcare datasets

Sales/retail analytics

Kaggle portfolio building

Global recognition & impact

Clinical Data Analytics Market Outlook

The clinical data analytics market has garnered significant attention in recent years, and as of 2023, it is valued at approximately USD 7.5 billion. The market is projected to reach an impressive USD 19.8 billion by 2032, growing at a robust CAGR of 11.2% from 2024 to 2032. This rapid expansion can be attributed to the increasing demand for data-driven decision-making in healthcare, driven by the necessity to enhance patient outcomes and streamline healthcare operations. The integration of advanced analytics in clinical processes allows healthcare providers to transform data into actionable insights, thereby improving quality of care and reducing costs.

The burgeoning healthcare sector's reliance on data analytics is a significant growth driver of the clinical data analytics market. Healthcare organizations are increasingly adopting analytics to manage the massive volume of data generated from various sources, including electronic health records (EHRs), clinical trials, and patient monitoring systems. The ability to harness this data effectively aids in developing personalized treatment plans, predicting disease outbreaks, and optimizing resource allocation. Moreover, government initiatives to promote the adoption of health information technologies and improve patient care quality further bolster the market's growth prospects. As a result, healthcare providers are investing heavily in analytics tools to stay competitive and compliant with regulations.

Another pivotal factor contributing to the market's growth is the emphasis on precision medicine, which necessitates advanced analytics to tailor medical treatment to individual characteristics. Precision health initiatives require analyzing vast datasets to identify patterns and correlations that inform personalized healthcare strategies. This approach is increasingly being recognized for its potential to enhance treatment efficiency and reduce adverse effects. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) technologies into clinical data analytics systems empowers healthcare professionals with predictive insights and automated decision support, further driving market expansion. The synergy between precision medicine and data analytics is transforming healthcare delivery by enabling more precise diagnostics and therapies.

The proliferation of cloud-based solutions is also a critical element propelling the clinical data analytics market. Cloud technology offers scalability, flexibility, and cost-effectiveness, allowing healthcare organizations to store and analyze large datasets efficiently. The shift towards cloud-based analytics solutions is particularly beneficial for small and medium-sized enterprises (SMEs) that may not have the resources for extensive on-premises infrastructure. Furthermore, the COVID-19 pandemic underscored the importance of real-time data access and collaboration, leading to accelerated adoption of cloud-based platforms. As healthcare providers continue to embrace digital transformation, the demand for cloud-based analytics solutions is expected to rise, contributing to market growth.

Big Data Analytics in Healthcare is revolutionizing the way healthcare providers manage and utilize vast amounts of data. By leveraging big data, healthcare organizations can gain deeper insights into patient care, operational efficiencies, and clinical outcomes. The ability to analyze large datasets allows for more accurate predictions and personalized treatment plans, ultimately enhancing patient care. Big data analytics also plays a crucial role in identifying trends and patterns that can lead to early detection of diseases and better resource management. As healthcare systems continue to generate massive volumes of data, the integration of big data analytics becomes essential for driving innovation and improving overall healthcare delivery.

Regionally, North America leads the clinical data analytics market, driven by the high adoption rate of advanced healthcare technologies and favorable government initiatives. The United States, in particular, has witnessed substantial investments in healthcare IT infrastructure and a strong focus on data-driven healthcare systems. Europe follows closely, with countries like Germany, the UK, and France promoting the digitization of healthcare services. The Asia Pacific region is expected to exhibit the highest growth rate during the forecast period, fueled by the increasing penetration of healthcare IT solutions in emerging ec

Healthcare Data Anonymization Services Market Outlook

According to our latest research, the global healthcare data anonymization services market size reached USD 1.42 billion in 2024, reflecting a robust expansion driven by increasing regulatory demands and heightened focus on patient privacy. The market is projected to grow at a CAGR of 15.8% from 2025 to 2033, with the total market value expected to reach USD 5.44 billion by 2033. This impressive growth trajectory is underpinned by the rising adoption of digital health solutions, stringent data protection laws, and the ongoing digitalization of healthcare records worldwide.

The primary growth factor fueling the healthcare data anonymization services market is the proliferation of electronic health records (EHRs) and the expanding use of big data analytics in healthcare. As healthcare providers and organizations increasingly leverage advanced analytics for improving patient outcomes, there is a corresponding surge in data generation. However, these vast datasets often contain sensitive patient information, making data anonymization essential to ensure compliance with regulations such as HIPAA, GDPR, and other regional privacy laws. The increasing frequency of data breaches and cyberattacks has further highlighted the importance of robust anonymization services, prompting healthcare organizations to prioritize investments in data privacy and security solutions. As a result, demand for both software and service-based anonymization solutions continues to rise, contributing significantly to market growth.

Another key driver for the healthcare data anonymization services market is the growing emphasis on research and clinical trials, which require the sharing and analysis of large volumes of patient data. Pharmaceutical and biotechnology companies, as well as research organizations, are increasingly collaborating across borders, necessitating the anonymization of datasets to protect patient identities and comply with international data protection standards. The adoption of cloud-based healthcare solutions has also facilitated the secure and efficient sharing of anonymized data, supporting advancements in personalized medicine and population health management. As organizations seek to balance innovation with compliance, the demand for advanced anonymization technologies that offer high accuracy and scalability is expected to accelerate further.

Technological advancements in artificial intelligence (AI) and machine learning (ML) are also shaping the future of the healthcare data anonymization services market. These technologies are enabling more sophisticated and automated anonymization processes, reducing the risk of re-identification while maintaining data utility for research and analytics. The integration of AI-driven tools into anonymization workflows is helping organizations streamline operations, minimize human error, and achieve greater compliance with evolving regulatory requirements. Additionally, the increasing availability of customizable and interoperable anonymization solutions is making it easier for healthcare organizations of all sizes to adopt and scale these services, thereby broadening the market’s reach and impact.

From a regional perspective, North America continues to dominate the healthcare data anonymization services market, accounting for the largest share in 2024. This leadership position is attributed to the presence of advanced healthcare infrastructure, widespread adoption of EHRs, and strict regulatory frameworks governing patient data privacy. Europe follows closely, driven by the enforcement of the General Data Protection Regulation (GDPR) and a strong culture of data protection. The Asia Pacific region is witnessing the fastest growth, propelled by increasing healthcare digitalization, government initiatives to modernize healthcare systems, and rising awareness of data privacy among patients and providers. Latin America and the Middle East & Africa are also experiencing steady growth, albeit from a smaller base, as healthcare organizations in these regions begin to prioritize data security and compliance.

Healthcare has long struggled to improve services through technology without further widening health disparities. With the significant expansion of digital health, a group of healthcare professionals and scholars from across the globe are proposing the official usage of the term “Digital Determinants of Health” (DDOH) to explicitly call out the relationship between technology, healthcare, and equity. This is the final paper in a series published in PLOS Digital Health that seeks to understand and summarize current knowledge of the strategies and solutions that help to mitigate the negative effects of DDOH for underinvested communities. Through a search of English-language Medline, Scopus, and Google Scholar articles published since 2010, 345 articles were identified that discussed the application of digital health technology among underinvested communities. A group of 8 reviewers assessed 132 articles selected at random for the mention of solutions that minimize differences in DDOH. Solutions were then organized by categories of policy; design and development; implementation and adoption; and evaluation and ongoing monitoring. The data were then assessed by category and the findings summarized. The reviewers also looked for common themes across the solutions and evidence of effectiveness. From this limited scoping review, the authors found numerous solutions mentioned across the papers for addressing DDOH and many common themes emerged regardless of the specific community or digital health technology under review. There was notably less information on solutions regarding ongoing evaluation and monitoring which corresponded with a lack of research evidence regarding effectiveness. The findings directionally suggest that universal strategies and solutions can be developed to address DDOH independent of the specific community under focus. With the need for the further development of DDOH measures, we also provide a framework for DDOH assessment.

According to Cognitive Market Research, the global Ai Training Data market size is USD 1865.2 million in 2023 and will expand at a compound annual growth rate (CAGR) of 23.50% from 2023 to 2030.

The demand for Ai Training Data is rising due to the rising demand for labelled data and diversification of AI applications.
Demand for Image/Video remains higher in the Ai Training Data market.
The Healthcare category held the highest Ai Training Data market revenue share in 2023.
North American Ai Training Data will continue to lead, whereas the Asia-Pacific Ai Training Data market will experience the most substantial growth until 2030.

Market Dynamics of AI Training Data Market

Key Drivers of AI Training Data Market

Rising Demand for Industry-Specific Datasets to Provide Viable Market Output

A key driver in the AI Training Data market is the escalating demand for industry-specific datasets. As businesses across sectors increasingly adopt AI applications, the need for highly specialized and domain-specific training data becomes critical. Industries such as healthcare, finance, and automotive require datasets that reflect the nuances and complexities unique to their domains. This demand fuels the growth of providers offering curated datasets tailored to specific industries, ensuring that AI models are trained with relevant and representative data, leading to enhanced performance and accuracy in diverse applications.

In July 2021, Amazon and Hugging Face, a provider of open-source natural language processing (NLP) technologies, have collaborated. The objective of this partnership was to accelerate the deployment of sophisticated NLP capabilities while making it easier for businesses to use cutting-edge machine-learning models. Following this partnership, Hugging Face will suggest Amazon Web Services as a cloud service provider for its clients.

(Source: about:blank)

Advancements in Data Labelling Technologies to Propel Market Growth

The continuous advancements in data labelling technologies serve as another significant driver for the AI Training Data market. Efficient and accurate labelling is essential for training robust AI models. Innovations in automated and semi-automated labelling tools, leveraging techniques like computer vision and natural language processing, streamline the data annotation process. These technologies not only improve the speed and scalability of dataset preparation but also contribute to the overall quality and consistency of labelled data. The adoption of advanced labelling solutions addresses industry challenges related to data annotation, driving the market forward amidst the increasing demand for high-quality training data.

In June 2021, Scale AI and MIT Media Lab, a Massachusetts Institute of Technology research centre, began working together. To help doctors treat patients more effectively, this cooperation attempted to utilize ML in healthcare.

www.ncbi.nlm.nih.gov/pmc/articles/PMC7325854/

Restraint Factors Of AI Training Data Market

Data Privacy and Security Concerns to Restrict Market Growth

A significant restraint in the AI Training Data market is the growing concern over data privacy and security. As the demand for diverse and expansive datasets rises, so does the need for sensitive information. However, the collection and utilization of personal or proprietary data raise ethical and privacy issues. Companies and data providers face challenges in ensuring compliance with regulations and safeguarding against unauthorized access or misuse of sensitive information. Addressing these concerns becomes imperative to gain user trust and navigate the evolving landscape of data protection laws, which, in turn, poses a restraint on the smooth progression of the AI Training Data market.

How did COVID–19 impact the Ai Training Data market?

The COVID-19 pandemic has had a multifaceted impact on the AI Training Data market. While the demand for AI solutions has accelerated across industries, the availability and collection of training data faced challenges. The pandemic disrupted traditional data collection methods, leading to a slowdown in the generation of labeled datasets due to restrictions on physical operations. Simultaneously, the surge in remote work and the increased reliance on AI-driven technologies for various applications fueled the need for diverse and relevant training data. This duali...

Data from: Doctoral dissertation; Preprint article entitled: Managers' and physicians’ perception of palm vein technology adoption in the healthcare industry. Formats of the files associated with dataset: CSV; SAV. SPSS setup files can be used to generate native SPSS file formats such as SPSS system files and SPSS portable files. SPSS setup files generally include the following SPSS sections: DATA LIST: Assigns the name, type, decimal specification (if any), and specifies the beginning and ending column locations for each variable in the data file. Users must replace the "physical-filename" with host computer-specific input file specifications. For example, users on Windows platforms should replace "physical-filename" with "C:\06512-0001-Data.txt" for the data file named "06512-0001-Data.txt" located on the root directory "C:". VARIABLE LABELS: Assigns descriptive labels to all variables. Variable labels and variable names may be identical for some variables. VALUE LABELS: Assigns descriptive labels to codes in the data file. Not all variables necessarily have assigned value labels. MISSING VALUES: Declares user-defined missing values. Not all variables in the data file necessarily have user-defined missing values. These values can be treated specially in data transformations, statistical calculations, and case selection. MISSING VALUE RECODE: Sets user-defined numeric missing values to missing as interpreted by the SPSS system. Only variables with user-defined missing values are included in the statements. ABSTRACT: The purpose of the article is to examine the factors that influence the adoption of palm vein technology by considering the healthcare managers’ and physicians’ perception, using the Unified Theory of Acceptance and Use of Technology theoretical foundation. A quantitative approach was used for this study through which an exploratory research design was utilized. A cross-sectional questionnaire was distributed to responders who were managers and physicians in the healthcare industry and who had previous experience with palm vein technology. The perceived factors tested for correlation with adoption were perceived usefulness, complexity, security, peer influence, and relative advantage. A Pearson product-moment correlation coefficient was used to test the correlation between the perceived factors and palm vein technology. The results showed that perceived usefulness, security, and peer influence are important factors for adoption. Study limitations included purposive sampling from a single industry (healthcare) and limited literature was available with regard to managers’ and physicians’ perception of palm vein technology adoption in the healthcare industry. Researchers could focus on an examination of the impact of mediating variables on palm vein technology adoption in future studies. The study offers managers insight into the important factors that need to be considered in adopting palm vein technology. With biometric technology becoming pervasive, the study seeks to provide managers with the insight in managing the adoption of palm vein technology. KEYWORDS: biometrics, human identification, image recognition, palm vein authentication, technology adoption, user acceptance, palm vein technology

Digital adherence technologies (DATs) have emerged as an alternative to directly observed therapy (DOT) for supervisions of tuberculosis (TB) treatment. We conducted a meta-analysis of implementation feedback obtained from people with TB and health care workers (HCWs) involved in TB REACH Wave 6-funded DAT evaluation projects. Projects administered standardized post-implementation surveys based on the Capability, Opportunity, Motivation, Behavior (COM-B) model to people with TB and their health care workers. The surveys included questions on demographics and technology use, Likert scale questions to assess capability, opportunity, and motivation to use DAT and open-ended feedback. We summarized demographic and technology use data descriptively, generated pooled estimates of responses to Likert scale questions within each COM-B category for people with TB and health care workers using random effects models, and performed qualitative analysis of open-ended feedback using a modified framework analysis approach. The analysis included surveys administered to 1290 people with TB and 90 HCWs across 6 TB REACH-funded projects. People with TB and HCWs had an overall positive impression of DATs with pooled estimates between 4·0 to 4·8 out of 5 across COM-B categories. However, 44% of people with TB reported taking TB medications without reporting dosing via DATs and 23% reported missing a dose of medication. Common reasons included problems with electricity, network coverage, and technical issues with the DAT platform. DATs were overall perceived to reduce visits to clinics, decrease cost, increase social support, and decrease workload of HCWs. DATs were acceptable in a wide variety of settings. However, there were challenges related to the feasibility of using current DAT platforms. Implementation efforts should concentrate on ensuring access, anticipating, and addressing technical challenges, and minimizing additional cost to people with TB.

The dataset contains the R script for performing panel estimation modeling based on Refinitiv data (not included due to copyright). Data headers mapped to Refinitiv are included. This dataset is attached to the paper entitled "The Impact of Knowledge Capital on Firm Profitability in the Technology and Healthcare Sectors" by the same author.

Artificial Intelligence in Diabetes Management Market Outlook

The global Artificial Intelligence in Diabetes Management market is projected to witness substantial growth over the forecast period, with the market size estimated to expand from USD 2.3 billion in 2023 to approximately USD 8.7 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 16.0%. This remarkable growth can be attributed to several factors, including the rising prevalence of diabetes worldwide, the increasing adoption of AI in healthcare, and the continuous advancements in AI technology that promise to enhance patient outcomes and streamline diabetes management practices.

One of the primary growth drivers of this market is the escalating prevalence of diabetes on a global scale. According to the International Diabetes Federation, diabetes affects over 537 million adults worldwide, and this number is projected to rise alarmingly over the coming years. This growing epidemic is fueling the demand for innovative and efficient management tools, with AI-based solutions emerging as a frontrunner in addressing these needs. AI technologies offer enhanced capabilities in monitoring glucose levels, predicting fluctuations, and personalizing treatment plans, thus improving patient compliance and outcomes. Moreover, the increasing awareness among patients and healthcare providers about the benefits of AI in managing chronic conditions further bolsters market growth.

The rapid technological advancements in artificial intelligence, particularly in machine learning and data analytics, are another significant factor propelling the market forward. These technologies enable the development of sophisticated algorithms capable of processing vast amounts of healthcare data to generate actionable insights. In diabetes management, this translates to more accurate glucose monitoring, predictive analytics for insulin delivery, and personalized patient management strategies. The ongoing research and development in AI technologies are expected to introduce future innovations that will further enhance the efficiency and efficacy of diabetes management solutions, thereby expanding the market's potential.

Additionally, the increasing integration of AI with existing healthcare infrastructure is transforming the diabetes management landscape. The collaboration between AI and traditional healthcare systems facilitates seamless data exchange, leading to more comprehensive patient profiles and informed decision-making. This integration also supports the shift towards value-based care, emphasizing improved patient outcomes and cost efficiency. Moreover, government initiatives and favorable reimbursement policies for AI-driven healthcare solutions are encouraging healthcare providers to adopt these technologies, creating lucrative opportunities for market growth.

From a regional perspective, North America currently holds the largest share in the AI in diabetes management market, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and significant investments in AI research and development. However, Asia Pacific is anticipated to witness the highest growth rate over the forecast period, supported by the increasing incidence of diabetes, growing healthcare expenditure, and the rapid adoption of digital health technologies in emerging economies. Europe also presents a promising market, with a strong focus on the integration of AI in healthcare systems and favorable regulatory environments. Together, these regions contribute to the dynamic and widespread expansion of the AI in diabetes management market globally.

Component Analysis

The component analysis of the Artificial Intelligence in Diabetes Management market reveals that the software segment holds a dominant position. This segment includes AI algorithms and platforms that facilitate glucose monitoring, insulin delivery, predictive analytics, and patient management. These software solutions are integral to the successful implementation of AI in diabetes management, as they process and interpret vast data sets to generate actionable insights. The continuous evolution of AI algorithms, focusing on improving accuracy and efficiency, is driving the growth of the software segment. Additionally, the increasing demand for personalized diabetes management solutions is further fueling the adoption of AI-powered software, as it offers customizable features tailored to individual patient needs.

Hardware components, although a smaller segment compared to software, play a crucial role in the AI diabetes management ecosystem. This segment encom

Artificial Intelligence (AI) in Healthcare Market Outlook

According to our latest research, the global Artificial Intelligence (AI) in Healthcare market size reached USD 24.6 billion in 2024, with a robust compound annual growth rate (CAGR) of 36.4% expected through the forecast period. By 2033, the market is projected to achieve a value of USD 349.5 billion, driven by increasing adoption of AI-powered solutions across healthcare ecosystems worldwide. The primary growth factor is the accelerating integration of AI technologies for enhancing diagnostics, streamlining patient management, and expediting drug discovery processes. As per our latest research, the sector is witnessing unprecedented investment and innovation, particularly in the realms of medical imaging, virtual assistants, and precision medicine, which are transforming the quality and efficiency of healthcare delivery.

One of the most significant growth drivers for the AI in Healthcare market is the surging demand for advanced data analytics and predictive modeling in medical decision-making. Healthcare providers are increasingly leveraging AI-powered tools to extract actionable insights from vast repositories of patient data, electronic health records (EHRs), and real-time monitoring devices. These technologies enable clinicians to identify disease patterns, predict patient outcomes, and personalize treatment regimens with remarkable accuracy. The proliferation of high-throughput medical imaging and wearable sensors has further amplified the need for scalable AI solutions, as traditional methods struggle to keep pace with the exponential growth in healthcare data. The ability of AI to process and interpret complex datasets in a fraction of the time required by human experts is revolutionizing diagnostics, leading to earlier interventions and improved patient prognoses.

Another crucial factor fueling the expansion of the AI in Healthcare market is the ongoing digital transformation initiatives across hospitals, clinics, and pharmaceutical companies. The COVID-19 pandemic has accelerated the adoption of telehealth, remote patient monitoring, and virtual care platforms, all of which rely heavily on AI algorithms for triage, symptom assessment, and risk stratification. Pharmaceutical and biotechnology firms are also harnessing AI to expedite drug discovery, optimize clinical trial design, and identify novel therapeutic targets, thereby reducing development timelines and costs. Additionally, AI-driven automation is streamlining administrative workflows, claims processing, and patient scheduling, resulting in significant operational efficiencies and cost savings for healthcare organizations. These advancements are fostering a data-driven culture that prioritizes evidence-based care and continuous improvement.

The growing acceptance of personalized medicine and precision healthcare is also a major catalyst for AI adoption in the sector. AI algorithms are instrumental in analyzing genetic, phenotypic, and lifestyle data to tailor treatment plans that maximize efficacy and minimize adverse effects. This paradigm shift towards individualized care is supported by advances in genomics, proteomics, and bioinformatics, all of which generate massive datasets that are ideally suited for AI-driven analysis. Furthermore, regulatory bodies are increasingly recognizing the value of AI in improving patient safety and outcomes, leading to a more favorable environment for the development and deployment of innovative AI solutions in healthcare. The convergence of these trends is expected to sustain the high growth trajectory of the AI in Healthcare market over the coming decade.

Regionally, North America currently dominates the global AI in Healthcare market, accounting for the largest share due to its advanced healthcare infrastructure, substantial investment in research and development, and early adoption of cutting-edge technologies. The United States, in particular, is a hub for AI innovation, with numerous startups and established players collaborating with academic institutions and healthcare providers. Europe follows closely, propelled by supportive regulatory frameworks and significant government funding for digital health initiatives. The Asia Pacific region is emerging as a high-growth market, driven by the rapid expansion of healthcare systems, rising prevalence of chronic diseases, and increasing focus on digitalization in countries such as China, Japan, and India. Latin America and the Middle East & Africa are also witnessing growing interest in AI-power

The global Artificial Intelligence (AI) Training Dataset market is projected to reach $1605.2 million by 2033, exhibiting a CAGR of 9.4% from 2025 to 2033. The surge in demand for AI training datasets is driven by the increasing adoption of AI and machine learning technologies in various industries such as healthcare, financial services, and manufacturing. Moreover, the growing need for reliable and high-quality data for training AI models is further fueling the market growth. Key market trends include the increasing adoption of cloud-based AI training datasets, the emergence of synthetic data generation, and the growing focus on data privacy and security. The market is segmented by type (image classification dataset, voice recognition dataset, natural language processing dataset, object detection dataset, and others) and application (smart campus, smart medical, autopilot, smart home, and others). North America is the largest regional market, followed by Europe and Asia Pacific. Key companies operating in the market include Appen, Speechocean, TELUS International, Summa Linguae Technologies, and Scale AI. Artificial Intelligence (AI) training datasets are critical for developing and deploying AI models. These datasets provide the data that AI models need to learn, and the quality of the data directly impacts the performance of the model. The AI training dataset market landscape is complex, with many different providers offering datasets for a variety of applications. The market is also rapidly evolving, as new technologies and techniques are developed for collecting, labeling, and managing AI training data.

Dataset name: asppl-dataset.csv

Version: 1.0

Dataset period: 06/07/2018- 05/25/2021

Dataset Characteristics: Multivalued

Number of Instances: 4861

Number of Attributes: 33

Missing Values: Yes

Area(s): Health and education

Sources:

• Primary: Unified Health System Virtual Learning Environment (AVASUS, in Portuguese: Ambiente Virtual de Aprendizagem do Sistema Único de Saúde) [1];

• Secondary:

  1. Brazilian Classification of Occupations (CBO, in Portuguese: Classificação Brasileira de Ocupação) [2];

  2. National Registry of Health Establishments (CNES, in Portuguese: Cadastro Nacional de Estabelecimentos de Saúde) [3]; and

  3. Brazilian Institute of Geography and Statistics (IBGE, in Portuguese: Instituto Brasileiro de Geografia e Estatística) [4].

Description: The data contained on the asppl-dataset.csv dataset (see Table 1) originates from participants of the technology-based educational course “Health care of Persons Deprived of Liberty”. The course is available on the Unified Health System Virtual Learning Environment [1]. This dataset provides elementary data for analyzing the course’s impact and reach, as well as the profile of its participants.

Oral diseases affect nearly 3.5 billion people, with the majority residing in low- and middle-income countries. Due to limited healthcare resources, many individuals are unable to access proper oral healthcare services. Image-based machine learning technology is one of the most promising approaches to improving oral healthcare services and reducing patient costs. Openly accessible datasets play a crucial role in facilitating the development of machine learning techniques. However, existing dental datasets have limitations such as a scarcity of Cone Beam Computed Tomography (CBCT) data, lack of matched multi-modal data, and insufficient complexity and diversity of the data. This project addresses these challenges by providing a dataset that includes 329 CBCT images from 169 patients, multi-modal data with matching modalities, and images representing various oral health conditions.

AI-Driven Hospital Readmission Predictor Market Outlook

According to our latest research, the global AI-Driven Hospital Readmission Predictor market size reached USD 1.43 billion in 2024, reflecting a robust momentum in the adoption of advanced predictive analytics within healthcare systems. The market is expected to grow at a CAGR of 18.8% from 2025 to 2033, culminating in an estimated value of USD 7.45 billion by 2033. This remarkable growth trajectory is primarily fueled by the increasing need to optimize patient care, reduce avoidable readmissions, and control healthcare costs through the integration of artificial intelligence in clinical workflows. As per our latest research, the sector’s expansion is being propelled by a convergence of regulatory pressures, technological advancements, and the growing emphasis on value-based care across the globe.

One of the most significant growth factors for the AI-Driven Hospital Readmission Predictor market is the mounting pressure on healthcare institutions to minimize readmission rates, which are often associated with financial penalties and deteriorating patient outcomes. Regulatory bodies in major markets, such as the Centers for Medicare & Medicaid Services (CMS) in the United States, have implemented stringent policies that penalize hospitals for excessive readmissions. This has compelled healthcare providers to seek innovative solutions that can proactively identify high-risk patients and intervene before readmissions occur. AI-driven predictive models, leveraging machine learning algorithms and vast datasets, have demonstrated substantial improvements in accurately forecasting readmission risks, thereby enabling targeted care interventions and personalized discharge planning. The integration of these solutions has become a strategic imperative for hospitals aiming to align with policy mandates while enhancing patient satisfaction and operational efficiency.

Another pivotal driver is the exponential growth in healthcare data and the parallel advancements in computational capabilities. The proliferation of electronic health records (EHRs), wearable devices, and remote monitoring technologies has resulted in an unprecedented volume of patient data, which, when harnessed effectively, can yield actionable insights for readmission prediction. AI-driven platforms are uniquely positioned to analyze complex, multidimensional data sets in real time, uncovering hidden patterns and risk factors that traditional statistical methods may overlook. This data-driven approach not only improves the accuracy of readmission predictions but also supports continuous learning and model refinement, ensuring that predictive tools remain relevant as clinical practices and patient populations evolve. The synergy between big data and AI has thus become a cornerstone of modern healthcare analytics, driving sustained investment in AI-driven readmission prediction solutions.

A third major growth catalyst is the shift towards value-based care and population health management, which prioritize outcomes over service volume. Healthcare payers and providers are increasingly incentivized to deliver high-quality, cost-effective care that reduces unnecessary hospital utilization. AI-driven hospital readmission predictors play a critical role in this paradigm by enabling proactive identification of at-risk populations, facilitating care coordination, and supporting resource allocation for post-discharge follow-up. These technologies empower care teams to implement evidence-based interventions, such as telehealth check-ins, medication reconciliation, and home health support, thereby reducing the likelihood of preventable readmissions. As healthcare systems worldwide strive to balance financial sustainability with clinical excellence, the adoption of AI-powered predictive analytics is expected to accelerate, further expanding the market’s reach and impact.

From a regional perspective, North America continues to dominate the AI-Driven Hospital Readmission Predictor market, accounting for the largest share in 2024, driven by advanced healthcare infrastructure, favorable reimbursement policies, and a strong focus on digital health innovation. However, Asia Pacific is emerging as the fastest-growing region, supported by rapid healthcare digitization, increasing investments in AI research, and government initiatives to improve healthcare quality and accessibility. Europe also demonstrates significant growth potential, particularly in countrie